COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF CYTOMEGALOVIRUS

• US 20110305708A1
• Filed: 05/17/2011
• Published: 12/15/2011
• Est. Priority Date: 03/10/2008
• Status: Active Grant

• Current Assignee: Theraclone Sciences, Inc.
• Original Assignee: Theraclone Sciences, Inc.
• Inventors: Olsen, Ole
• Granted Patent: US 8,268,309 B2
• Time in Patent Office: Days
• US Class Current: 424/159.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/42 viral
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/088 Varicella-zoster virus
• CPC Class Codes: C07K 16/089 Cytomegalovirus
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: G01N 2333/045 Cytomegalovirus
• CPC Class Codes: G01N 33/56994 Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus

Abstract

The present invention provides novel anti-cytomegalovirus antibodies and related compositions and methods. These antibodies may be used in the diagnosis, prevention, and treatment of cytomegalovirus infection.

Claims

1-10. -10. (canceled)

11. A method for the treatment or prevention of a CMV infection in a subject, comprising administering to the subject a composition comprising an isolated anti-CMV antibody, wherein said antibody comprises,

(a) a V_H region comprising

(i) a V_H CDR1 region comprising the amino acid sequence of GFTSS (SEQ ID NO:

60);

(ii a V_H CDR2 region comprising the amino acid sequence of VISSDANDKQ (SEQ ID NO;

     61);

(iii) a V_H CDR3 region comprising the sequence of DGTCSGGNCYSGLIDY (SEQ ID NO;

     59); and

(b) a V_L region comprising

(i) a V_L CDR1 region comprising the amino acid sequence of RASQSVGGYLA (SEQ ID NO;

     43);

(ii) a V_L CDR2 region comprising the amino acid sequence of ASIRAT (SEQ ID NO;

     64);

(iii) a V_L CDR3 region comprising the amino acid sequence of HQRSNWPPLT (SEQ ID NO;

     65).

12. The method of claim 11, wherein the method further comprises administering an anti-viral treatment.

13. The method of claim 12, wherein said anti-viral treatment is ganciclovir, foscarnet, cidofovir, valganciclovir, and intravenous immunoglobulin (IVIG).

14. The method of claim 11, wherein said antibody is administered prior to or after exposure to CMV.

15. The method of claim 11, wherein said antibody is administered at a dose sufficient to neutralize CMV infection.

18. The method of claim 11, wherein said antibody binds an epitope of the glycoprotein b (gB) envelope protein of the CMV virus.

19. The method of claim 18, wherein said epitope comprises the antigenic determinant 2 site 1 of gB, gp116.

20. The method of claim 11, wherein said composition further comprises an anti-viral treatment.

21. The method of claim 20, wherein said anti-viral treatment is ganciclovir, foscarnet, cidofovir, valganciclovir, and intravenous immunoglobulin (IVIG).

22. The method of claim 11, wherein the composition further comprises a second anti-CMV antibody.

23. The method of claim 11, wherein said antibody is operably-linked to a therapeutic agent or a detectable label.

16-17. -17. (canceled)